MA-PRECISELY
17.5.2023 15:31:33 CEST | Business Wire | Press release
Precisely, the global leader in data integrity, today announced the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005070/en/
Precisely, the global leader in data integrity, announces the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market. (Photo: Business Wire)
RapidCX empowers organizations to provide a better, more effective customer experience through data-driven, personalized, communications. This is particularly important for highly regulated industries such as financial services, insurance, and telecommunications, where the pressure is on to deliver more personalized and dynamic customer experiences to stay competitive, while also navigating increasingly complicated regulatory requirements.
Announced at the Trust ‘23 Data Integrity Summit, RapidCX allows organizations to solve challenges such as disjointed customer communications, compliance with changing regulations, and siloed legacy systems to:
- Improve Efficiencies – replace manual customer experience processes with an automated solution that enables business users to harness data from across all systems.
- Enhance Customer Engagement – capture data-driven insights to quickly and easily personalize and automate omnichannel communications, including e-mails, SMS messages, chatbot conversations, interactive video and more.
- Enable Better Governance – ensure compliance with end-to-end communications tracking, delivery tracing, and archiving. Easy-to-manage governance controls make even complicated industry regulations easier to follow.
“The launch of RapidCX is a significant industry event and a real game changer for Precisely, particularly in highly regulated markets,“ said Kaspar Roos, Founder & CEO at Aspire. “Precisely has brought together a wide variety of standalone capabilities into a comprehensive, fully managed cloud-based platform, providing a simplified way for customers to get access to modern customer-focused technologies without the need for extensive integration. The launch positions Precisely favorably to meet the needs of a new generation of CCM buyers found in marketing, customer experience, and the line-of-business.”
The announcement of the new platform is well-timed, with customer loyalty being harder to come by in recent years due to shifts in consumer behavior, rising competition, and economic pressures. In fact, a recent PwC survey showed that more than half of consumers (55%) would stop buying from a company, even if they otherwise liked them, after having several bad experiences – with a further 8% saying they would stop after just one negative experience.
With the rollout of RapidCX, organizations worldwide can now easily and dynamically deliver satisfying, personalized experiences, no matter how, where or when the customer chooses to interact. When combined with the Precisely portfolio of data integrity solutions, organizations can ensure they are powering customer communications delivery with trusted data, helping to win lasting loyalty and, ultimately, accelerate business growth.
“Businesses can no longer apply a one-size-fits-all approach to customer engagement. Today's customers expect extraordinary experiences, and trusted data is the cornerstone for delivering them,” said Greg Van den Heuvel, Executive Vice President and General Manager – Engage Solutions at Precisely. “Forward-thinking organizations are turning to cloud hosted integrated customer engagement platforms, fueled with accurate, consistent, and contextual data, to revolutionize their approach to customer communications.”
Learn more about RapidCX here.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
